- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
April 12, 2021Robins Kaplan Executives Recognized by Twin Cities Business
-
April 1, 2021Robert Bennett Named a Midwest Trailblazer
-
March 31, 2021Robins Kaplan Attorneys Earn 2021 Readers' Choice Awards from JD Supra
-
April 28, 2021Creating the Audit Clause for Today’s Compliance Review
-
April 29, 2021International Intellectual Property: Challenges of Cross-Border Litigation
-
May 5, 12, and 19, 2021Second Annual AI Legal Summit
-
April 2, 2021Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
-
Spring 2021Fiduciary or Foe? Revisiting Meinhard v. Salmon
-
Spring 2021Shareholder Risks in Mergers and Acquisitions
-
April 14, 2021Financial Daily Dose 4.14.2021 | Top Story: Crypto Exchange Coinbase Makes Public Debut on Nasdaq
-
April 13, 2021Financial Daily Dose 4.13.2021 | Top Story: Ant Group Agrees to Sweeping Overhaul to Appease Chinese Regulators
-
April 12, 2021Financial Daily Dose 4.12.2021 | Top Story: Chinese Regulators Hit Alibaba With $2.8B Antitrust Fine
Beyond Preemption of Generic Drug Claims
2015
Recent research indicates that the current cost of generic medications in the United States is the highest in history. Many patients are no longer able to afford life saving medications that were once affordable only five years ago. Concurrent to the rising prices of generic drugs, pharmaceutical companies have lauded preemption as a necessary and viable solution to combat the increasing prices. Two recent Supreme Court decisions, PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett, have agreed with this logic, and have attempted to pervert the Hatch-Waxman Act, and its corresponding ANDA approval process to shield generic drug manufacturers from liability.
Recent research indicates that the current cost of generic medications in the United States is the highest in history.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Eric M. Lindenfeld
Associate
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.